Improving Lives Through Nuclear Medicine™

News

News

  • September 22, 2021

    Eckert & Ziegler’s GalliaPharm®, exclusively distributed by Jubilant Radiopharma, approved for use with NETSPOT in Canada

  • 16 March 2021

    Jubilant Radiopharma and Isotopia Molecular Imaging Enter into a Strategic Partnership to Further Advance the Field of Radiotherapeutics

    Isotopia Molecular Imaging Limited (Isotopia) and Jubilant Radiopharma, a business division of Jubilant Pharma Limited, have entered into a strategic commercial partnership.

  • 4 November 2020

    Jubilant Radiopharma and SOFIE Biosciences Ink Strategic Partnership Deal to Further Advance the Field of Molecular Imaging & Therapeutics

  • 31 August 2020

    Eckert & Ziegler‘s GalliaPharm® to be distributed by Jubilant Radiopharma in Canada

  • 10 August 2020

    Jubilant Radiopharma and Navidea Biopharmaceuticals Sign Binding Memorandum of Understanding for Commercialization Partnership

  • March 18th, 2020

    OUR COMPANY RESPONSE TO COVID-19

  • February 17th, 2020

    JUBILANT RECEIVES FAVORABLE RULINGS FROM THE U.S. PATENT OFFICE INVALIDATING BRACCO RUBIDIUM-INFUSION-SYSTEM PATENTS

  • January 29th, 2020

    Jubilant Radiopharma Receives Approval from Health Canada for Drax Exametazime® a Product Used to Diagnose Intra-Abdominal Infection and Inflammatory Bowel Disease

  • December 11th, 2019

    FAVORABLE RULING FROM THE U.S. COURTS FOR RUBY-FILL®

  • October 25th, 2019

    JUBILANT AWARDED PREMIER PURCHASING AGREEMENT

  • October 03rd, 2019

    JUBILANT TO DISTRIBUTE STRONTIUM-89 CHLORIDE INJECTION USP IN THE U.S.

  • August 28th, 2019

    QUALITY AND SAFETY IS AT THE CORE OF WHAT WE DO

  • August 12th, 2019

    ITC FOUND THAT JUBILANT IMPORTATION AND SALE OF RUBY-FILL IN THE U.S. DOES NOT VIOLATE SECTION 337 OF THE TARIFF ACT OF 1930

  • July 23rd, 2019

    IMPORTANT INFORMATION FOR CANADIAN NUCLEAR PHARMACISTS

  • July 19th, 2019

    Important information for U.S. nuclear pharmacists and commercial radiopharmacies

  • June 17th, 2019

    Introducing Jubilant Radiopharma

  • June 06th, 2019

    RUBY Rubidium Elution System™ receives CE Mark Certificate

  • March 26th, 2019

    New and Important Safety Information as Requested by the FDA

  • February 08th, 2019

    Campaign to Support FDA Approved Products

  • September 28th, 2018

    Family Health Campaign

  • August 13th, 2018

    Jubilant initiates I-131 MIBG OPTIMUM Trial

  • April 06th, 2018

    Important Customer Communication

  • December 30th, 2017

    JDI receives FDA approval for new pulmonary indications for DRAXIMAGE® DTPA

  • November 06th, 2017

    JDI to attend Miami Thyroid Oncology Symposium 2018

  • October 27th, 2017

    Jubilant DraxImage receives FDA approval for 12-Hour shelf-life for DRAXIMAGE® MAA

  • September 28th, 2017

    Jubilant DraxImage receives approval from Health Canada for the RUBY Elution System™ (RbES)

  • September 27th, 2017

    ASNC 2013 in Chicago, IL

  • May 05th, 2017

    Jubilant Pharma to acquire Triad Isotopes

  • January 19th, 2017

    JDI participates to SNMMI Mid-Winter in Phoenix Arizona

  • April 09th, 2017

    Jubilant DraxImage Appoints New Sales and Business Operations VP

  • October 21st, 2016

    Michael Rossi: New President of Jubilant DraxImage.

  • October 03rd, 2016

    JDI RECEIVES FDA APPROVAL for products

  • September 30th, 2016

    No impact on I-131 supply from Chalk River shutdown

  • May 12th, 2016

    JDI and CYC Licensing Agreement Update

  • May 03rd, 2016

    Not all Iodine-131 is created equal

  • January 06th, 2016

    Count On It DRAXIMAGE® MAA 350K Particles Campaign

  • December 03rd, 2015

    Canada- Radioactive Iodine in Differentiated Thyroid Cancer; Patient Video

  • December 03rd, 2015

    USA – Radioactive Iodine in Differentiated Thyroid Cancer; Patient Video

  • October 09th, 2015

    Jubilant DraxImage launches HICON® in Colombia

  • September 14th, 2015

    JDI-Cyclopharm Technegas Announcement

  • September 11th, 2015

    September is Thyroid Cancer Awareness month

  • September 01st, 2015

    ASNC 2015 – Washington, DC, Sept. 17-20 – booth 801

  • July 07th, 2015

    New Endocrine Brand Portfolio Manager

  • May 19th, 2015

    SNMMI 2015 – Baltimore, MD June 6 to 9 – Booth 853

  • May 08th, 2015

    Canada: temporary shortage of Xenon-133

  • April 20th, 2015

    Jubilant DraxImage Files Citizen Petition with the FDA

  • December 08th, 2014

    New Lung Imaging Portfolio Manager

  • November 20th, 2014

    RSNA 2014: Chicago, IL

  • October 20th, 2014

    New Director – Manufacturing Operations

  • September 22nd, 2014

    ASNC 2014, Boston, MA

  • August 19th, 2014

    New Director – Commercial Operations for Latin America

  • May 15th, 2014

    MAA Pricing: FAQ

  • May 12th, 2014

    New USA Sales Director

  • April 18th, 2014

    MAA Pricing: Investing in the Future of MAA & DTPA

  • March 01st, 2014

    Action to ensure sustainability and continuity of supply of MAA/DTPA in USA

  • January 13th, 2014

    Jubilant DraxImage Appoints New Marketing Director

  • November 08th, 2013

    Japanese SNM 2013 in Fukuoka, Japan

  • September 06th, 2012

    ASNC 2012 in Baltimore, MD

We use cookies to recognize your repeat visits and preferences, as well as to measure the effectiveness
of campaigns and analyze traffic. If you continue to use this site we will assume your acceptance.